1,242 filings
Page 3 of 63
6-K
SNY
Sanofi
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
SNY
Sanofi
27 Apr 23
Current report (foreign)
9:32am
SC TO-T/A
PRVB
Provention Bio Inc
27 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
PRVB
Provention Bio Inc
26 Apr 23
Third party tender offer statement (amended)
6:16am
6-K
SNY
Sanofi
24 Apr 23
Current report (foreign)
9:55am
6-K
SNY
Sanofi
11 Apr 23
Current report (foreign)
1:02pm
SC TO-T/A
SNY
Sanofi
10 Apr 23
Third party tender offer statement (amended)
4:38pm
S-8
SNY
Sanofi
30 Mar 23
Registration of securities for employees
1:36pm
SC TO-T
PRVB
Provention Bio Inc
24 Mar 23
Third party tender offer statement
7:10am
6-K
SNY
Sanofi
23 Mar 23
Current report (foreign)
4:00pm
SC TO-C
PRVB
Provention Bio Inc
17 Mar 23
Information about tender offer
4:16pm
6-K
SNY
Sanofi
14 Mar 23
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
12:05pm
SC TO-C
PRVB
Provention Bio Inc
13 Mar 23
Information about tender offer
4:15pm
S-8 POS
SNY
Sanofi
13 Mar 23
Registration of securities for employees (post-effective amendment)
11:40am
6-K
SNY
Sanofi
13 Mar 23
Current report (foreign)
7:38am
6-K
SNY
Sanofi
6 Mar 23
Current report (foreign)
11:57am
6-K
SNY
Sanofi
24 Feb 23
FDA approves once-weekly ALTUVIIIOâ„¢, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
5:20pm
IRAN
SNY
Sanofi
24 Feb 23
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
10:56am
20-F
2022 FY
SNY
Sanofi
Annual report (foreign)
24 Feb 23
10:25am
6-K
SNY
Sanofi
21 Feb 23
Sanofi announces change in R&D leadership
12:52pm